Navigating Drug Rebates Post American Rescue Plan Act

Health Delegates • November 15, 2023

Navigating the New Terrain of Drug Rebates Post-American Rescue Plan Act


The American Rescue Plan (ARP) Act of 2021 is set to initiate a paradigm shift not just in Medicaid rebates but across the entire spectrum of pharmaceutical rebates. This legislative change is expected to ripple through the healthcare industry, altering the dynamics of drug pricing and manufacturer rebates in a way that stakeholders must carefully navigate.



The end of rebate cap: a broader perspective


The ARP Act's removal of the statutory cap on rebates that drug manufacturers pay marks a seismic shift that extends its tremors beyond Medicaid, affecting the entire pharmaceutical rebate ecosystem. With the removal of the cap. manufacturers will face a new financial reality where the potential for rebate payments could exceed the previous 100% average manufacturer price (AMP) limit, compelling a reevaluation of pricing strategies across manufacturers. This policy change is expected to incentivize manufacturers to prevent price hikes beyond inflation rates, as any significant increase could lead to a proportionally larger rebate obligation. The industry must now prepare for a more complex rebate negotiation process, as payers may expect greater flexibility, concessions, and lower AMP considering the uncapped rebate potential. This will lead to lower rebate payments for those adjusted AMP products.



The ripple effect on brand drugs: an industry-wide impact


The uncapping of rebates is poised to have its most pronounced effect on brand drugs, particularly those with high list prices or those that have historically been at the AMP rebate cap. For manufacturers, this could translate into a steep increase in rebate liabilities, potentially reshaping the profitability landscape for certain high-cost drugs. The broader impact on the market could lead to increased competition among manufacturers to avoid the high rebate costs, possibly driving down drug prices overall. Stakeholders across the healthcare system, including pharmacies, insurers, and patients, will need to stay informed as these pricing changes could affect everything from formulary decisions to out-of-pocket costs.



Proactive measures by manufacturers: a strategic shift


In response to the ARP Act, manufacturers are likely to explore various strategies to mitigate increased rebate liabilities, such as adjusting list prices and exploring alternative pricing models. Lowering list prices, while maintaining overall net cost, could become a common approach to manage the balance between maintaining market share and controlling rebate expenses.


Manufacturers are also considering restructuring their discount programs, potentially leading to a reduction in the volume of discounts offered to maintain a sustainable Best Price. The industry could witness an increased focus on value-based pricing agreements, where reimbursement is tied to patient outcomes rather than volume, to navigate the updated rebate landscape.



Health Delegates' approach: adapting to industry-wide changes


Health Delegates is proactively adjusting its pricing models to reflect the anticipated changes inWAC and rebate amounts, ensuring transparency and predictability for their clients. By incorporating these changes into their pricing strategies now, Health Delegates is positioning itself as a leader in the transition to the post-ARP Act rebate environment. The organization's true pass-through payment model exemplifies a commitment to fair and transparent dealings, which may become an industry standard in the wake of the ARP Act's changes. Health Delegates' approach could prompt other industry players to adopt similar transparent practices, fostering a more open and predictable rebate market.



Looking ahead: preparing for a new era of rebates


The ARP Act's AMP cap removal is set to ripple through the rebate system, impacting Medicaid and beyond, marking a transformative period in the pharmaceutical industry. As the industry approaches the January 2024 threshold, it is imperative for all stakeholders, including manufacturers, healthcare providers, and payers, to grasp the full scope of these changes. The healthcare sector must remain agile, strategic, and proactive to successfully navigate the new financial landscapes that will emerge from this significant policy shift. The coming years will likely see a period of adjustment as the market responds to the new pricing and rebate structures, with long-term implications for drug pricing, market competition, and patient access.



Health Delegates' commitment to our clients


At Health Delegates we work with our clients to understand this impact and ensure you have information on how this may impact your rebate dollars. We arm you with information to alleviate the uncertainty. As changes are implemented in 2024, we will continue to keep our finger on the pulse and communicate possible impacts.

Subscribe for Exclusive Industry Insights

Contact Us

The Formulary-Rebate Connection: Why Lowest-Net-Cost Strategy Is More Important Than Ever

By Health Delegates • June 2, 2026
In a volatile drug pricing environment, the plans that win are the ones that think beyond WAC.

Your Rebate Report Is Missing Something

By Health Delegates • May 11, 2026
Here’s What Both Sides of the Table Should Be Asking For

Unlocking Savings: The Power of Transparent Reporting

By Health Delegates • February 5, 2025
The Power of Transparent Reporting in Pharmacy Benefits Managing pharmacy benefit costs is one of the most complex challenges faced by benefits managers, large employer groups, and health plans consultants. As prescription drug prices continue to rise, finding a way to efficiently manage pharmacy spending and maximize savings is crucial. While rebate programs can offer significant savings, many traditional models lack the transparency and granularity needed to fully understand where savings are coming from—and where they may be slipping through the cracks. At Health Delegates, we’ve revolutionized rebate management with a robust online reporting suite that delivers unparalleled visibility into pharmacy spend, empowering health plans and employer groups to optimize their benefits programs and increase their savings. With over 4 million covered lives under our management, we have the experience and expertise to handle diverse requirements with precision and care. Effective Rebate Management through Transparent Reporting One of the core strengths of Health Delegates lies in our ability to offer a 360-degree view of your pharmacy spending. Our reporting suite is designed to give you thorough, real-time insights into how and where rebates are earned, down to the net cost of each claim. This transparency paves the way for smarter, more informed decision-making when it comes to managing pharmacy benefits. Whether you’re looking to track rebate performance, improve formulary strategies, or optimize drug savings, our reporting tools provide actionable data that allows you to make savings decisions with confidence. Our Approach: Simplifying Cost Management At Health Delegates, we take a straightforward approach to rebate solutions. Our goal is to provide a clear picture of your overall pharmacy benefit costs, so you can make data-driven decisions that optimize savings. We understand that balancing rebates, clinical formulary solutions, and broader healthcare costs can be complex. That’s why we offer a comprehensive solution that enables you to manage all these factors effectively, with a focus on reducing your net drug costs. We aim to be your strategic partner , delivering the insights you need to optimize your pharmacy benefits and maximize your rebate opportunities. With our suite of customizable reports, you can easily drill down into essential data and identify opportunities for savings. Key Reporting Tools to Maximize Savings Health Delegates offers a suite of customizable, client-centric reports that give you a transparent and comprehensive understanding of your pharmacy spending. Here’s an overview of the key reports we provide: Executive Summaries Our executive summaries offer a concise yet thorough overview of your rebate management, summarizing key data points, performance trends, and areas for improvement. This high-level report gives health plans and employer groups an easily digestible snapshot of their rebate program’s effectiveness, helping you make informed decisions and adjust strategies where needed. Operational Reports Our operational reports provide critical insights into the details of your claims. This includes reports on claim submissions, rejected claims, and the reasons behind rejections. These reports are standardized for easy integration into your data warehouse or analytics engine, making it simple to manage rebates and address anomalies as they occur. Financial Reports Timely and accurate financial forecasting is essential for budgeting and planning. Health Delegates provides financial reports that provide estimates of expected rebates, as well as detailed tracking of specific rebate payments received. These reports enable transparent tracking of funds and their sources, drilling down to the claim level, including NDC, to demonstrate the direct value of your rebate program. Clinical Reports Our clinical reports analyze formulary product distribution and provide insights into which drugs are being used most frequently. This helps identify how drug utilization impacts overall rebate earnings and provides valuable data for formulating clinical program strategies. These insights are essential for adjusting formularies and ensuring you’re maximizing rebate potential. Maximize Your Pharmacy Savings with Health Delegates Health Delegates is committed to helping health plans and employer groups unlock the full potential of their pharmacy benefit programs through transparent, detailed reporting. Our tools empower you to make better-informed decisions, optimize your drug spending, and drive greater savings—all while maintaining the high standards of care your members expect. Ready to optimize your pharmacy benefits? Contact us at hdinquiries@healthdelegates.com today to learn how our comprehensive reporting and innovative rebate solutions can help you take control of your pharmacy spending.

Healthcare Integrity: Investigating the Ethical Dilemmas of Co-Manufacturing

By Health Delegates • November 8, 2024
Explore how co-manufacturing in the pharmaceutical sector impacts drug costs and consumer choice, and learn about Health Delegates' approach to transparent healthcare solutions.

Staying Informed: The Key to Navigating Complex Rebate Models

By Health Delegates • August 28, 2024
Learn how Health Delegates' transparent rebate model helps organizations avoid risks and ensures clarity in managing pharmacy benefits.

Rethinking Rebate Models: Transparency and True Cost Savings

By Health Delegates • July 30, 2024
Discover how Health Delegates offers a transparent rebate model that ensures true cost savings without the pitfalls of traditional rebate guarantees.

Health Delegates: We Are More Than Just Rebates

By Health Delegates • July 10, 2024
Learn how Health Delegates' proprietary formularies and utilization management can transform your pharmacy strategy and cut costs.

Shifting Focus: Driving Low Net Cost in Pharmacy Benefits Management

By Deb Curry • June 26, 2024
Discover Health Delegates' unique approach to Pharmacy Benefits Management (PBM). Our latest blog post explains how focusing on transparency and the lowest net costs can drastically reduce your pharmacy expenses and align incentives.

Drug Manufacturer Rebates: Claims Reporting & Simplifying the Process

By Health Delegates • May 29, 2024
Discover how Health Delegates can simplify rebate programs, ensuring transparency and maximizing savings with effective, clear strategies.

Navigating the Complexities of Benefits Management: The Case for Transparency and Alignment

By Health Delegates • March 20, 2024
In the intricate landscape of corporate benefits management, navigating the array of consulting services and pharmacy benefit managers (PBMs) presents its own set of challenges. Opting for consolidated solutions promises simplicity and efficiency on the surface but often conceals a deeper issue: the risk of misaligned incentives leading to inflated costs and compromised benefits management. Understanding the Pitfalls of Consolidated Solutions The allure of streamlined services through a single provider or consultant is understandable, aiming to reduce administrative burdens and potentially harness cost savings. Yet, this approach can inadvertently foster a setting where the interests of consultants or PBMs do not fully align with those of the company and its employees. Recently filed court cases accuse employers of overpaying for prescription drugs, exemplifies the possible neglect in securing competitive pricing, hinting at a broader issue of oversight. Compensation models for consultants that tie back to the volume or cost of procured services and medications can, albeit unintentionally, favor higher-cost options. This structure may prioritize the consultant's financial gain over the best interests of the company and its workforce, clouding the cost-effectiveness and benefits of management decisions and potentially undermining the fiduciary duty owed to employees. The Advantages of a Decentralized Approach to Benefits Management Choosing a decentralized model for managing benefits introduces multiple benefits, including: Competitive Pricing Assurance : Engaging with various providers for different benefits aspects allows for effective comparison and ensures optimal value. Improved Transparency: A decentralized model offers clearer insight into the costs and benefits of each package component, vital for budget management and justifying employee benefits. Fiduciary Duty Compliance : Critical evaluation and selection of benefits components align with the company’s responsibility to act in the best interests of its employees. Strategies for Effective Benefits Management Adopting a thoughtful approach to avoid misaligned incentives and honor fiduciary duties involves several key actions: Routine Audits : Regular evaluations of benefits plans can spotlight inflated costs or misalignments with employee needs. Diverse Vendor Engagement : Collaborating with multiple vendors encourages competitive pricing and terms. Transparent Vendor Selection : A clear and competitive vendor selection process ensures the identification of the best services and prices available. The recently filed case against J&J serves as a valuable lesson for companies to scrutinize their benefits management approach. While consolidated services offer appeal, it’s crucial to be mindful of potential misalignments and the significance of maintaining a competitive and transparent environment. Shifting towards a decentralized strategy can better align with employee interests, uphold fiduciary responsibilities, and unveil potential cost savings. Explore Decentralized Solutions with Health Delegates Facing the complexities and possible conflicts of consolidated benefits management, companies can benefit from expert guidance in this area. Health Delegates specializes in assisting companies with decoupling and decentralizing pharmacy benefits, ensuring alignment with fiduciary responsibilities and optimizing value and cost-effectiveness for employees. Reevaluating your benefits strategy with a focus on decentralization could enhance transparency, competitive pricing, and fiduciary duty compliance. Health Delegates is poised to support you in this journey, offering customized solutions that cater to your unique needs and objectives. Reach out to Health Delegates to discover how we can aid in refining your pharmacy benefit management and rebate strategies . Our expertise is designed to navigate the intricacies of benefits management, aligning your approach with your organizational values and the well-being of your employees.